Suspected Hepatic Encephalopathy
Patient with chronic liver disease + altered mental status/neurological changes
All Pathways
GastroenterologyManagement
Hepatic Encephalopathy Management (AASLD/EASL 2022)
Hepatic Encephalopathy Management (AASLD/EASL 2022): Suspected Hepatic Encephalopathy → Confirm HE Diagnosis → Grade HE Severity (West Haven) → Grade 1:...
Pathway Overview
13 steps
Algorithm Steps
13 total
01Start 02Action Confirm HE Diagnosis
Rule out other causes of altered mental status
- Known chronic liver disease/cirrhosis
- Assess for precipitants
- Rule out: hypoglycemia, electrolyte disorders, infection, intracranial pathology, drugs/toxins
- CT head if focal neuro signs or no improvement
03Decision Grade HE Severity (West Haven)
Determine grade to guide management intensity
- Covert HE: Grade 0-1 (psychometric testing abnormal)
- Overt HE: Grade 2-4 (clinically apparent)
04Action Grade 1: Trivial Lack of Awareness
Shortened attention, sleep disturbance
- May have asterixis on exam
- Start lactulose
- Identify precipitants
05Action Identify & Treat Precipitants
Most episodes have identifiable trigger
- Infection (UTI, SBP, pneumonia) - start antibiotics
- GI bleeding - treat source
- Constipation - lactulose
- Electrolyte disorders (hyponatremia, hypokalemia) - correct
- Dehydration - IV fluids cautiously
- Medications (opioids, benzos) - discontinue
- Dietary protein excess - rare, don't restrict protein
06Action Lactulose (First-Line)
Non-absorbable disaccharide
- Initial: 25-45 mL PO q1-2h until bowel movement
- Maintenance: 25-45 mL PO BID-QID
- Target: 2-3 soft BM/day
- Lactulose enema: 300 mL in 1L water (retain 30-60 min)
07Action Add Rifaximin (Second-Line)
For lactulose failure or recurrence prevention
- 550 mg PO BID
- Continue lactulose (combination therapy)
- Reduces HE recurrence by ~50%
- No significant resistance or systemic absorption
08Decision Assess Response
Improvement expected within 24-48 hours
09Outcome HE Resolved
Continue secondary prophylaxis
- Lactulose maintenance (2-3 BM/day)
- Rifaximin 550 mg BID after first overt HE episode
- Optimize nutrition (1.2-1.5 g/kg protein)
- Avoid precipitants
10Warning Refractory HE
Consider additional interventions
- Re-evaluate for missed precipitants
- Consider TIPS occlusion if post-TIPS HE
- Liver transplant evaluation
- Zinc supplementation (if deficient)
- L-ornithine L-aspartate (LOLA) - limited evidence
- Path rejoins step 08Shared downstream outcome
11Action Grade 2: Disorientation, Lethargy
Obvious personality change, inappropriate behavior
- Asterixis present
- Lactulose + precipitant treatment
- Consider admission
- Path rejoins step 05Shared downstream outcome
12Warning Grade 3: Somnolent, Confused
Arousable but marked confusion
- Hospital admission required
- Lactulose NG if unable to take PO
- Close monitoring
- Path rejoins step 05Shared downstream outcome
13Warning ⚠️ Grade 4: Coma
ICU admission, consider ALF evaluation
- Intubate for airway protection
- Rule out cerebral edema
- Lactulose enemas if intubated
- Consider transplant evaluation
- Path rejoins step 05Shared downstream outcome
Guideline Source
AASLD/EASL Practice Guideline on Hepatic Encephalopathy in Chronic Liver Disease
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- West Haven criteria are subjective
- Ammonia levels do not correlate with severity
- Lactulose dosing requires individualization
- Rifaximin cost may limit access
- Must rule out other causes of altered mental status
Applicable Regions
USEUGlobal
EU: EASL guidelines jointly developed
US: AASLD 2022 is current standard
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Glasgow-Blatchford Bleeding Score
Upper GI bleed risk stratification and need for intervention
Open page
Compare
AttendMe.ai vs UpToDate
See how this pathway workflow compares against UpToDate.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the Hepatic Encephalopathy Management (AASLD/EASL 2022)?
The Hepatic Encephalopathy Management (AASLD/EASL 2022) is a management clinical algorithm for Gastroenterology. It provides a structured decision tree to guide clinical decision-making, based on AASLD/EASL Practice Guideline on Hepatic Encephalopathy in Chronic Liver Disease.
What guideline is the Hepatic Encephalopathy Management (AASLD/EASL 2022) based on?
This algorithm is based on AASLD/EASL Practice Guideline on Hepatic Encephalopathy in Chronic Liver Disease (DOI: 10.1002/hep.32327).
What are the limitations of the Hepatic Encephalopathy Management (AASLD/EASL 2022)?
Known limitations include: West Haven criteria are subjective; Ammonia levels do not correlate with severity; Lactulose dosing requires individualization; Rifaximin cost may limit access; Must rule out other causes of altered mental status. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Hepatic Encephalopathy Management (AASLD/EASL 2022) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free